Member Info for Yorkshirepragma

B, absolutely. I noted from another paper that ca25% of paediatric cases have to withdraw from cardiac adverse effects , when delivery is a highly successful
treatment.
What an advance Av can deliver, and a truly exceptional one for sufferers .
GLA

# Illustrates the high frequency of adverse effects in chemotherapy.

https://ascopubs.org/doi/abs/10.1200/JCO.22.02221

https://pharmaboardroom.com/articles/roche-banking-on-ma-spree-to-propel-it-back-up-global-pharma-rankings/

22 article but highly relevant…has more to do.
GLA

Yes…II pressure being applied ?

Most telling figure is the $4bn+/- paid for similar fledglings by majors @phase1/2.
QED
GLA

Potential @ this stage..3/1..?
GLA

https://stats.oecd.org/Index.aspx?DataSetCode=QASA_7II_INDIC

https://na.linkedin.com/posts/alastair-smith-1b4b9111_times-letters-30-jan-2023-activity-7025777741383770113-ixbg

Certainly upbeat, what we really need though is USA interest!
Yeha…
GLA

https://www.thepharmaletter.com/article/oncology-continues-to-drive-m-a-and-dealmaking-activity

Or someone will…oncology M& A annum runs at $70bn + ….see table fyi.
GLA

That’s Notes.

And a prediction ..offers within 3m
As an old bold pharmo.
….

Nites.
- Avacta offers an essentially ‘ complete’ package .
- Has multiple threads
- Near proven efficacy .
- 6000 market significant.
- all majors in need of derisked packages.
- several early stagers already taken out at $4bn +/-

GLA

-

https://www.forbes.com/sites/ritanumerof/2022/11/10/if-pharma-companies-dont-overhaul-their-rd-model-quickly-cancer-patients-in-desperate-search-for-new-cures-will-be-left-behind/?sh=6d7c377c2e33

NASDAQ imminent. AS has essentially’ declared’ …just find a shell and away…
GLA

A more relevent read for the weekend.
Flags up!….

https://www.forbes.com/sites/ritanumerof/2022/11/10/if-pharma-companies-dont-overhaul-their-rd-model-quickly-cancer-patients-in-desperate-search-for-new-cures-will-be-left-behind/?sh=6d7c377c2e33

Gm, yes indeed, speaking as an old bold ICI/ Zenacite, results like this are a dream and are a rarity.
My guess…already interest ,
Inevitable.
Regards

https://www.forbes.com/sites/ritanumerof/2022/11/10/if-pharma-companies-dont-overhaul-their-rd-model-quickly-cancer-patients-in-desperate-search-for-new-cures-will-be-left-behind/?sh=6d7c377c2e33

AS et al have created a ‘significant change’ in Chemo.
If you read through the lit. either for scientific interest or investment, comparable potential ( emphasise this) uplift in treat-ability has not been achieved .
Moreover it’s via a known efficacious drug change with background.
Dix & Other platform drugs arising are likely to be equally positive products.
Nothing like this has been seen for a while.
AS will inevitably be seeing licensing options emerging ,and significant ‘interest’ in Av ,by many.
GLA

‘Always a brush through before you sell the house”…
GLA

https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html

On this basis ,and with PR arising this should be an interesting week!?
GLA